TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Grifols ( (ES:GRF) ) just unveiled an update.
Grifols has announced that its subsidiary, Grifols Biotest Holdings GmbH, will submit a public offer to purchase all ordinary and non-voting preferred shares of Biotest AG for delisting. This strategic move aims to enhance Grifols’ market position by integrating Biotest’s operations, with the offer subject to approval by the German Federal Financial Supervisory Authority.
More about Grifols
Grifols is a global healthcare company specializing in the production of plasma-derived medicines and transfusion medicine. The company focuses on enhancing the health and well-being of people around the world through innovative solutions in the biopharmaceutical industry.
YTD Price Performance: -5.35%
Average Trading Volume: 219,514
Technical Sentiment Signal: Strong Buy
Current Market Cap: €5.34B
Find detailed analytics on GRF stock on TipRanks’ Stock Analysis page.